Innovate UK

EnrichMyCare is a technology company that specializes in developing a personal health platform. This platform aims to centralize and streamline care coordination, particularly for children, by improving communication among families, healthcare providers, social care services, and educators. It enables instant sharing of records and remote monitoring of the child's welfare, simplifying the complex process of managing care. The company's solutions help to accelerate care, enhance patient monitoring and engagement, prevent disabilities, and ultimately reduce healthcare costs.

Mulder specializes in blockchain-based traceability solutions for the medical device industry. It develops a network platform that offers real-time visibility and traceability across the entire supply chain, from raw material sourcing to patient application. This enables healthcare providers and manufacturers to verify device provenance, ensure compliance, and enhance patient safety.

Mulder specializes in blockchain-based traceability solutions for the medical device industry. It develops a network platform that offers real-time visibility and traceability across the entire supply chain, from raw material sourcing to patient application. This enables healthcare providers and manufacturers to verify device provenance, ensure compliance, and enhance patient safety.

Kaydiar is a medical device company focused on developing innovative, cost-effective solutions for wound care, particularly for pressure injuries. They specialize in offloading technology, creating products such as orthotic devices, bed mattresses, wheelchair cushions, and prosthetic sleeves to relieve pressure and promote healing.

Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Naitive is a population health company focused on improving patient care through AI-enabled clinical pathways and medical device technology. The company develops software that employs artificial intelligence, clinical data, and digital interventions to enhance the identification, treatment, and coordination of care for chronic diseases. By leveraging advanced computational capabilities, Naitive aims to support clinicians in transforming patient care while simultaneously reducing costs, time, and the failure rates commonly associated with chronic disease management.

Siloton is a medical device manufacturer focused on creating diagnostic imaging devices for ophthalmology. The company specializes in developing advanced portable optical coherence tomography devices designed to address challenges in eye care. Their hand-held sub-surface imaging technology allows for home-based scanning, providing users with the ability to monitor their eye health and contribute to the prevention of avoidable blindness.

Nami Surgical specializes in developing and providing advanced robotic surgery technology. Their core offering is ultrasonic surgical tools designed to enhance the current robotic-assisted surgery market. By simplifying and making procedures safer, they expand the use of robots in surgeries requiring ultrasonic devices, thereby improving clinical outcomes and patient care. Their solutions provide surgeons with intuitive, high-performance, and maneuverable instruments for complex surgical tasks.

Medicsen is a start-up focused on healthcare innovation, primarily through the development of advanced technology solutions. A notable project is GlycSen, a needle-free drug delivery device aimed at providing a painless treatment option for individuals with insulin-dependent diabetes. This device integrates data from continuous glucose meters and user-inputted information, utilizing a learning algorithm to facilitate real-time monitoring. It features a chatbot interface that allows patients to easily track their condition, enhancing their ability to manage diabetes effectively. Through these innovations, Medicsen aims to improve the quality of life for those living with chronic diseases.

SleepCogni is focused on developing innovative sleep aid technology that facilitates a personalized wind-down process to enhance sleep quality. The company's device, activated manually, utilizes sensors worn on the user's index finger to monitor key physiological and behavioral indicators, including heart rate, mental alertness, skin temperature, and movement. By employing cognitive behavioral therapy through biofeedback—delivered via visual, auditory, and tactile cues—SleepCogni aims to help users relearn healthy sleep patterns. This approach is designed to assist individuals in overcoming insomnia and improving their overall sleep cycle, offering a tailored solution to address common sleep challenges.

machineMD is a medical device company based in Switzerland, with a subsidiary in Boston, that focuses on advancing the fields of neuroscience and ophthalmology. The company aims to enhance the measurement of brain function, striving for timely and accurate diagnoses of brain disorders. By collaborating with a global network of clinical and research partners, machineMD seeks to extend the diagnostic capabilities of specialized medical practitioners to primary and secondary care settings. Its innovative automated device replaces traditional, manual assessments of eye movements and pupillary function, allowing medical assistants to conduct faster and more objective examinations. This technology provides ophthalmologists and neurologists with reliable measurements, ultimately improving patient care in the diagnosis of neurological conditions.

GaitQ Limited, founded in 2019 and based in Oxfordshire, United Kingdom, specializes in developing a medical device aimed at assisting individuals with Parkinson's disease in overcoming freezing of gait. The company's product, known as the GaitThaw device, is small and portable, designed to utilize clinically proven sensory cues. These cues facilitate the re-establishment of the connection between the brain and the body, enabling patients to walk more smoothly and confidently.

Occuity Ltd is a company based in Reading, United Kingdom, that focuses on the research, design, and manufacture of non-contact optical instruments for healthcare diagnostics and monitoring. Founded in 2019, it offers a range of handheld devices, including pachymeters, pupillometers, and keratometers, which are utilized in both human and veterinary optometry. These instruments employ light to analyze the eye, facilitating direct measurements that assist optometrists and ophthalmologists in diagnosing and monitoring various health conditions, such as diabetes and Alzheimer's disease. By providing innovative non-contact solutions, Occuity aims to enhance the effectiveness and accessibility of diagnostic and screening technologies in the healthcare sector.

Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.

PulmoBiomed is a developer of innovative sampling technology that offers a non-invasive method for clinicians and researchers to collect biological samples. The company's primary product is a passive fluid aerosol sampler designed to capture exhaled breath condensate and environmental particles, effectively segregating them by size. This technology addresses critical challenges in sample collection, such as preventing contamination and loss, while ensuring the generation of highly reproducible data with digital molecular precision. By focusing on metabolomic profiling and biological agent capture, PulmoBiomed aims to enhance the accuracy and reliability of respiratory diagnostics and research.

Lucida Medical is a developer of healthcare technology that utilizes artificial intelligence to enhance the detection and diagnosis of cancer. The company has created software that supports the analysis of MRI scans, focusing on applications for cancer diagnosis, screening, and management. Its flagship product, Pi, is designed specifically for the diagnosis of prostate cancer through multiparametric or diffusion MRI and has received CE marking as a medical device. By integrating imaging and multi-omics biomarkers, Lucida Medical aims to provide clinicians with tools that make cancer detection more accurate, accessible, cost-effective, and rapid. The company is interested in collaborating with investors and hospital partners who share its commitment to early cancer detection.

Bioliberty is a medtech start-up focused on creating innovative rehabilitation solutions for individuals with degenerative and traumatic conditions. The company develops robotic gloves that leverage artificial intelligence to facilitate muscle recovery. By utilizing assistive robotics and rehabilitative devices, Bioliberty aims to support patients suffering from various ailments, including stroke, motor neuron disease, multiple sclerosis, rheumatoid arthritis, and osteoarthritis. These devices are designed to assist users in overcoming hand weakness, enabling them to perform daily tasks more effectively and enhance their hand strength, ultimately promoting greater independence and comfort in their own homes.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Kalium Health Ltd is a company focused on improving kidney care through innovative medical technology. Based in Cambridge, United Kingdom, it designs and manufactures a finger-prick blood test specifically for measuring blood potassium concentration. This test aims to facilitate early treatment for patients, reducing the complications and costs associated with traditional testing methods. By leveraging advanced electrolyte sensing technology, Kalium Health provides patients with accurate, real-time data essential for managing cardiorenal diseases. The company’s first product addresses a significant risk in kidney disease, a condition that imposes substantial financial burdens on healthcare systems. With a clear regulatory pathway and a targeted market strategy, Kalium Health is poised to transform patient care and enhance outcomes for millions affected by kidney disease.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

Boost Innovations focuses on developing products specifically for women, with a particular emphasis on enhancing comfort and confidence. The company specializes in creating breast prostheses designed to provide both security and usability for users, especially those who have undergone surgery. Their innovative breast forms are crafted to remain secure within post-surgery underwear and are suitable for various activities, including swimming and exercising. By prioritizing breathability and functionality, Boost Innovations aims to meet the unique needs of its customers, ensuring they feel comfortable and confident in their daily lives.

Orthonika Limited, established in 2014 and based in London, United Kingdom, specializes in the development and manufacturing of MenisciKnit, an anatomical meniscus replacement designed to address severe meniscus injuries. These injuries can significantly impair mobility and lead to complications such as osteoarthritis and the need for knee arthroplasty. Current treatment options, including partial meniscectomy and allograft transplantation, often fall short, leaving a significant unmet need in the market. MenisciKnit employs a unique fiber-reinforced material structure that closely mimics the natural meniscus, aiming to restore proper knee biomechanics. This innovative approach not only provides a solution for those with severe meniscus damage but also supports patients in resuming active lifestyles and offers a comprehensive alternative to traditional knee-related treatments.

Rescape Innovation Limited, based in Cardiff, United Kingdom, specializes in the design and manufacture of healthcare equipment focused on enhancing patient experiences. Incorporated in 2017, the company is at the forefront of using virtual reality technology to address various healthcare challenges, including pain management, anxiety reduction, and communication support. Through its innovative virtual reality distraction therapy, Rescape Innovation aims to improve patient outcomes and overall well-being in clinical settings.

Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

Spacebands develops software and wearable technology focused on enhancing workplace safety. The company's primary product is a wearable watch that monitors social distancing and decibel levels. This device alerts users through beeping and vibrating when they are too close to another individual wearing the same technology. By providing an affordable and effective solution for social distancing and contact tracing, Spacebands aims to create safer environments in various professional settings.

PatientMpower specializes in remote monitoring solutions aimed at patients with chronic diseases, particularly those with respiratory conditions. The company develops applications that integrate with devices such as spirometers and pulse oximeters, allowing patients to conduct measurements at home. These devices connect to a smartphone application, which transmits real-time data to healthcare providers. This integration supports healthcare professionals in delivering high-quality care and enhances patient outcomes by facilitating continuous monitoring. Additionally, the data collected contributes to research efforts aimed at improving treatment options for chronic conditions.

Fallouh Healthcare specializes in the development and manufacturing of medical devices and AI-based software for cardiac surgery. Their products aim to enhance patient safety and streamline surgical workflows. Key offerings include systems for monitoring and protecting the heart during surgery, and AI-driven tools to detect and prevent complications like tamponade.

WeWALK Limited is a company based in London, United Kingdom, that develops innovative mobility tools for visually impaired individuals. Founded in 2017, WeWALK has created a smart cane equipped with advanced technology, including an ultrasonic sensor that detects obstacles above chest level and vibrates to alert users of nearby objects. This smart cane is enhanced by the WeWalk mobile application, which facilitates outdoor navigation, wayfinding, and public transportation integration. The company aims to empower visually impaired individuals by promoting independence and safety in their daily lives, thereby fostering social inclusion and transforming mobility experiences through the use of artificial intelligence and modern technology.

Emm is focused on creating innovative consumer health tools that empower individuals to manage their health effectively. The company has developed a wearable device aimed at enhancing reproductive health by providing users with biometric data that offers actionable insights into their unique reproductive profiles. This technology enables users and their healthcare providers to identify potential health issues and optimize reproductive health outcomes, thereby improving the overall quality of life. Emm's approach combines advanced technology with specialized knowledge to enhance personal health management.

Brainstem is a DePIN to collect and utilise wearable health data. Our mission is to revolutionize healthcare and improve lives through remote screening, ongoing monitoring, digital treatment alternatives, and tools to share data with practitioners, researchers, and others. We are committed to building a network of users who are willing to share their data and embracing collaboration with smart minds to speed innovation. With our vision of being a 24/7 virtual health assistant specializing in sleep, mental, cardio, and neuro health, we are at the forefront of digital health.

52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.

Silveray specializes in the development of affordable large-area direct conversion detectors for the X-ray imaging market. The company employs advanced technology that utilizes nanoparticle-based X-ray conversion materials, produced as semiconductor ink, which are then deposited onto a pixel backplane. This innovative approach enables high-performance X-ray imaging and generates an electrical current in response to detected X-ray photons. By focusing on sustainability and cost-effectiveness, Silveray aims to enhance imaging capabilities for healthcare and various industries.

Acurable Limited is a MedTech start-up based in London that specializes in the design and commercialization of a wearable sensor-based health care device aimed at diagnosing and managing respiratory conditions in a non-invasive manner. The company's flagship product, AcuPebble, allows for the diagnosis of sleep apnea and the monitoring of various respiratory and cardiac conditions through advanced algorithms that analyze acoustic signals. This technology, which emerged from a decade of research at Imperial College London, provides more accurate readings than existing solutions, significantly reducing the risk of misdiagnosis. AcuPebble is designed for home use, requiring no specialist training, which helps lower healthcare costs. Acurable's mission is to gain a comprehensive understanding of human biosignals to ensure that treatable conditions do not result in preventable deaths.

ProtonDx is a diagnostic platform that specializes in molecular testing services, focusing on the rapid and precise detection of multiple pathogens from samples. The company develops point-of-care diagnostic test devices aimed at assisting healthcare professionals in diagnosing infectious diseases. Utilizing innovative microchip technology, ProtonDx integrates molecular biology with machine learning, allowing for swift deployment in clinical settings. This enables healthcare organizations to efficiently manage infected patients and monitor pandemic situations in real-time. ProtonDx emphasizes speed, sensitivity, specificity, and convenience in its offerings, positioning itself as a vital resource for frontline healthcare staff.

At OCUWELL, we're revolutionising eye care with our innovative, cloud-based solutions designed to make quality eye care accessible and affordable for everyone, everywhere. Our flagship product is a portable corneal topographer addressing the global need for essential diagnostic tools in treating corneal disorders, which affect over 2.2 billion people. With a unique B2B and SaaS business model, backed by 25 years of leading scientific research, we're on track to transform the delivery of eye care worldwide.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

Anya is a company focused on providing support to mothers and families during breastfeeding and early parenthood. It develops an application that employs 3D interactive technology and artificial intelligence to assist parents in acquiring essential parenting and infant feeding skills. This innovative platform offers virtual companionship and connects families with peer-to-peer and professional support, enabling them to access guidance anytime and anywhere. By leveraging specialist support, Anya aims to enhance the parenting experience and address health disparities in maternity care, fostering a supportive community for new parents.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

SleepCogni is focused on developing innovative sleep aid technology that facilitates a personalized wind-down process to enhance sleep quality. The company's device, activated manually, utilizes sensors worn on the user's index finger to monitor key physiological and behavioral indicators, including heart rate, mental alertness, skin temperature, and movement. By employing cognitive behavioral therapy through biofeedback—delivered via visual, auditory, and tactile cues—SleepCogni aims to help users relearn healthy sleep patterns. This approach is designed to assist individuals in overcoming insomnia and improving their overall sleep cycle, offering a tailored solution to address common sleep challenges.

MiiCare is an innovative company that has developed an AI-powered Home Care Platform tailored for older adults, their families, and caregivers. This platform aims to transform living spaces into safe and connected environments, promoting active aging through a focus on prevention and personalized care. MiiCare integrates various technologies, including telehealth devices, passive sensors, and acoustic sensing, to monitor health determinants such as physical environment, vital signs, and mental well-being. Central to its approach is a conversational AI named Monica, which serves as a Digital Health Coach. Monica engages with users to ensure medication adherence, encourage healthy habits, and provide personalized digital therapeutic content. By enabling remote care delivery and comprehensive assessments of well-being, MiiCare supports caregivers in reducing costs and hospitalizations while enhancing the overall quality of care for aging individuals.

MiiCare is an innovative company that has developed an AI-powered Home Care Platform tailored for older adults, their families, and caregivers. This platform aims to transform living spaces into safe and connected environments, promoting active aging through a focus on prevention and personalized care. MiiCare integrates various technologies, including telehealth devices, passive sensors, and acoustic sensing, to monitor health determinants such as physical environment, vital signs, and mental well-being. Central to its approach is a conversational AI named Monica, which serves as a Digital Health Coach. Monica engages with users to ensure medication adherence, encourage healthy habits, and provide personalized digital therapeutic content. By enabling remote care delivery and comprehensive assessments of well-being, MiiCare supports caregivers in reducing costs and hospitalizations while enhancing the overall quality of care for aging individuals.

Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.

Oxford Heartbeat develops innovative medical device software designed to enhance the planning and execution of cardiovascular surgeries. The company's platform allows surgeons to visualize critical information about a patient's anatomy by providing insights into blood vessels, tissue, and bone structures. This advanced technology, which leverages predictive computations, big data, and artificial intelligence, enables medical professionals to rehearse procedures and select the most effective surgical scenarios tailored to individual patients. By improving surgical preparation, Oxford Heartbeat aims to reduce complication rates and associated healthcare costs while enhancing overall patient care. The company is currently conducting prospective clinical trials in NHS hospitals, supported by the UK government's AI in Health and Care Awards.

CryoLogyx is an early-stage biotechnology company focused on advancing cell cryopreservation technology to enhance drug discovery processes. By employing innovative methods that utilize cryoprotectants, CryoLogyx transforms the freezing, storage, and transportation of cells. This proprietary technology ensures the delivery of viable, ready-to-use cells and cell therapies, allowing healthcare researchers to access these resources in the desired format. The company's approach aims to improve the efficiency and effectiveness of cell-based research in the fields of medicine discovery, diagnostics, and cell therapy.

Bea Fertility is a monthly subscription program that provides users with at-home fertility treatment and ovulation tracking. The kits offered by Bea Fertility include an intracervical insemination device, as well as pregnancy tests, fertility trackers, and sperm donation pots. Bea Fertility democratizes effective and affordable fertility treatment for individuals and couples who are having difficulty conceiving.

Camallergy Limited, based in Cambridge, United Kingdom, is a biopharmaceutical company established in 2015 that focuses on developing and manufacturing oral immunotherapy drugs and other pharmaceutical products specifically for food allergies. The company's primary offering is a novel oral immunotherapy designed to treat peanut allergies, which aims to provide patients with "bite-proof" protection within 14 weeks of therapy. This patient-centric treatment addresses the urgent needs of millions suffering from food allergies and is rooted in clinical research conducted at Cambridge University Hospitals NHS Foundation Trust. Camallergy's unique intellectual property and treatment regimen exemplify its commitment to improving the quality of life for individuals affected by these allergies.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Ingenion Medical is a medical device company focused on developing innovative solutions for patients suffering from chronic urinary retention and incontinence. The company's products aim to mimic natural urination, thereby eliminating the need for drainage bags. By prioritizing clinically relevant and cost-effective designs, Ingenion Medical addresses critical issues related to urinary flow and control, enhancing the quality of life for its users.

MiiCare is an innovative company that has developed an AI-powered Home Care Platform tailored for older adults, their families, and caregivers. This platform aims to transform living spaces into safe and connected environments, promoting active aging through a focus on prevention and personalized care. MiiCare integrates various technologies, including telehealth devices, passive sensors, and acoustic sensing, to monitor health determinants such as physical environment, vital signs, and mental well-being. Central to its approach is a conversational AI named Monica, which serves as a Digital Health Coach. Monica engages with users to ensure medication adherence, encourage healthy habits, and provide personalized digital therapeutic content. By enabling remote care delivery and comprehensive assessments of well-being, MiiCare supports caregivers in reducing costs and hospitalizations while enhancing the overall quality of care for aging individuals.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

Ablatus Therapeutics Limited is a medical device company based in Norwich, United Kingdom, established in 2015. The company specializes in developing innovative tissue ablation technology aimed at treating challenging and often inoperable solid cancer tumors. Its proprietary Bimodal Electric Tissue Ablation technology utilizes radiofrequency energy delivered through a specialized probe to create localized heating that destroys targeted tissues. This approach provides healthcare professionals with advanced clinical options for treating cancer, ultimately improving patient outcomes.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

Vitrue Health focuses on developing digital technology to address musculoskeletal issues through accurate measurement and analysis. Their flagship product, VIDA, is a comprehensive service aimed at reducing problems such as back and neck pain among desk workers by ensuring compliance with ergonomic standards for remote, office, and hybrid environments. Utilizing advanced AI, VIDA assesses workspace quality and empowers employees with knowledge to improve their environments, thereby enhancing their overall well-being. Additionally, Vitrue's EVVA technology employs depth sensors for clinical-grade assessments in orthopaedics and injury prevention, offering precise evaluations of functional movements throughout rehabilitation. By leveraging computer vision and biomechanics, Vitrue Health not only collects and analyzes health data but also provides actionable insights to both clinicians and patients, promoting early detection of issues and informed decision-making in treatment plans. Their mission is to transform musculoskeletal healthcare and significantly reduce pain for millions of individuals.

Arete Medical Technologies is a startup focused on developing medical devices and software aimed at precision management of chronic diseases, with an initial emphasis on asthma and chronic obstructive pulmonary disease (COPD). The company creates digital therapeutic devices that allow for personalized and preventative care in chronic respiratory conditions. Arete Medical utilizes advanced hardware and software technologies to reduce sensor costs and incorporates artificial intelligence and biomechanical modeling to enhance patient outcomes. This approach aims to support medical practitioners in improving patient care and increasing the efficiency of healthcare systems.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

Kheiron Medical Technologies Limited is a company focused on enhancing breast cancer detection through its innovative product, Mia, an intelligent assessment tool for mammography. Incorporated in 2016 and based in London with additional offices in San Francisco, Budapest, and Amsterdam, Kheiron aims to improve the efficiency, consistency, and accuracy of radiology reporting by integrating advanced deep learning techniques with radiological expertise. The company's mission is to radically enhance outcomes for cancer patients by advancing precision radiology, thereby providing women with better chances in the fight against cancer. Through ongoing research and development, Kheiron strives to transform cancer detection and treatment, marking a significant step forward in the realm of healthcare technology.

Arete Medical Technologies is a startup focused on developing medical devices and software aimed at precision management of chronic diseases, with an initial emphasis on asthma and chronic obstructive pulmonary disease (COPD). The company creates digital therapeutic devices that allow for personalized and preventative care in chronic respiratory conditions. Arete Medical utilizes advanced hardware and software technologies to reduce sensor costs and incorporates artificial intelligence and biomechanical modeling to enhance patient outcomes. This approach aims to support medical practitioners in improving patient care and increasing the efficiency of healthcare systems.

ExplantLab is an independent research organization located in Newcastle upon Tyne, United Kingdom. The company focuses on exploring the connections between patient genetics and the design, manufacture, and performance of medical devices. By integrating genetic insights into its research, ExplantLab aims to enhance the effectiveness and safety of medical devices, ultimately improving the quality of life for patients.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

OKKO Health specializes in developing home-monitoring applications for eye health, utilizing advanced algorithms that integrate vision science, computer science, and game technology. Their software allows patients at high risk for eye diseases to monitor their eyesight from home, promoting early detection and personalized care. By enabling self-assessment between clinical appointments, OKKO Health aims to enhance patient engagement and streamline appointment scheduling. The company’s innovative approach combines scientific research with practical applications in clinical practice and drug development, providing a reliable method for measuring vision and predicting potential deterioration in eye health.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Echopoint Medical Ltd, established in 2018 and headquartered in London, specializes in developing medical devices that incorporate optical-fibre based sensors. The company leverages optical fibre sensing technologies to enhance precision in invasive cardiology and other minimally invasive procedures, with a focus on transforming the diagnosis and treatment of cardiovascular diseases. Echopoint's innovative devices aim to improve patient outcomes, reduce healthcare costs, and minimize surgical complications.

Vitrue Health focuses on developing digital technology to address musculoskeletal issues through accurate measurement and analysis. Their flagship product, VIDA, is a comprehensive service aimed at reducing problems such as back and neck pain among desk workers by ensuring compliance with ergonomic standards for remote, office, and hybrid environments. Utilizing advanced AI, VIDA assesses workspace quality and empowers employees with knowledge to improve their environments, thereby enhancing their overall well-being. Additionally, Vitrue's EVVA technology employs depth sensors for clinical-grade assessments in orthopaedics and injury prevention, offering precise evaluations of functional movements throughout rehabilitation. By leveraging computer vision and biomechanics, Vitrue Health not only collects and analyzes health data but also provides actionable insights to both clinicians and patients, promoting early detection of issues and informed decision-making in treatment plans. Their mission is to transform musculoskeletal healthcare and significantly reduce pain for millions of individuals.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

BIOS Health is a pioneering company focused on developing neural digital therapies by leveraging data from the human nervous system. By identifying neural biomarkers that correlate nerve activity to specific medical conditions, BIOS aims to revolutionize precision medicine. Their research offers the potential for innovative treatments for a range of chronic diseases, including hypertension, diabetes, and neurodegenerative disorders such as Parkinson's and Alzheimer's. Co-founded by experts from Cambridge University, the team includes professionals from diverse fields such as neuroscience, machine learning, and biotechnology. Additionally, BIOS is working on prosthetic connectors that standardize connections between bionic devices and neural systems, facilitating neural control and feedback for amputees. This dual approach positions BIOS at the forefront of improving the quality of life for individuals with chronic conditions and those requiring prosthetic solutions.

Bioinduction specializes in the development of neuromodulation devices aimed at treating chronic pain and various neurological disorders. The company's innovative products include a skull-mounted deep brain stimulation (DBS) platform that offers advanced features such as neural recording and target steering. These enhancements not only streamline surgical procedures but also prioritize patient comfort by improving the device's placement compared to conventional DBS systems. Bioinduction's focus on creating faster and simpler solutions in deep brain stimulation reflects its commitment to advancing therapeutic options for patients with challenging medical conditions.

Oxford Heartbeat develops innovative medical device software designed to enhance the planning and execution of cardiovascular surgeries. The company's platform allows surgeons to visualize critical information about a patient's anatomy by providing insights into blood vessels, tissue, and bone structures. This advanced technology, which leverages predictive computations, big data, and artificial intelligence, enables medical professionals to rehearse procedures and select the most effective surgical scenarios tailored to individual patients. By improving surgical preparation, Oxford Heartbeat aims to reduce complication rates and associated healthcare costs while enhancing overall patient care. The company is currently conducting prospective clinical trials in NHS hospitals, supported by the UK government's AI in Health and Care Awards.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, particularly through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging tool allows for real-time detection of cancer during surgical procedures, which can significantly reduce the chances of cancer recurrence and the necessity for reoperations. By optimizing the performance of robotic cancer surgery, Lightpoint Medical aims to provide healthcare professionals with advanced tools that enhance surgical decision-making and improve patient outcomes, ultimately contributing to cost savings within the healthcare system.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

Arete Medical Technologies is a startup focused on developing medical devices and software aimed at precision management of chronic diseases, with an initial emphasis on asthma and chronic obstructive pulmonary disease (COPD). The company creates digital therapeutic devices that allow for personalized and preventative care in chronic respiratory conditions. Arete Medical utilizes advanced hardware and software technologies to reduce sensor costs and incorporates artificial intelligence and biomechanical modeling to enhance patient outcomes. This approach aims to support medical practitioners in improving patient care and increasing the efficiency of healthcare systems.

Renephra Ltd. is a medical device company based in Manchester, United Kingdom, established in 2009. It specializes in developing innovative Transdermal Fluid Removal (TFR) technology aimed at addressing fluid overload and chronic conditions such as oedema and lymphoedema. The company's devices utilize a micro-needle system combined with negative pressure therapy to facilitate minimally invasive fluid removal from the skin. This technology targets significant clinical needs within vascular and oncology patients, representing a large and underserved market estimated at £1 billion globally. Having achieved proof of concept in human trials, Renephra is currently seeking funding to advance its device development and feasibility studies.

GripAble Ltd. designs and develops digital therapy devices aimed at improving rehabilitation for individuals with movement impairments such as stroke, arthritis, cerebral palsy, and trauma. Founded in 2017 and based in London, the company offers a portable, wireless handgrip device that connects to a mobile application. This application allows users to engage with therapy games while providing assessment and training for hand and arm functions. GripAble's innovative approach focuses on making therapy more accessible and engaging for patients, enabling them to practice essential daily tasks in a fun and motivating way. By combining hardware and software, GripAble addresses the needs of over 500 million people worldwide who face challenges with arm mobility, facilitating self-training both in clinical settings and at home.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

SleepCogni is focused on developing innovative sleep aid technology that facilitates a personalized wind-down process to enhance sleep quality. The company's device, activated manually, utilizes sensors worn on the user's index finger to monitor key physiological and behavioral indicators, including heart rate, mental alertness, skin temperature, and movement. By employing cognitive behavioral therapy through biofeedback—delivered via visual, auditory, and tactile cues—SleepCogni aims to help users relearn healthy sleep patterns. This approach is designed to assist individuals in overcoming insomnia and improving their overall sleep cycle, offering a tailored solution to address common sleep challenges.

Jellagen, established in 2013 and headquartered in Pembroke Dock, UK, specializes in harvesting jellyfish for the production of high-grade native collagen. This collagen, derived from jellyfish, is used in various medical and research applications, including tissue engineering, regenerative medicine, stem cell research, and cell culture studies. Jellagen supplies its collagen products in both solution and powder forms, catering to the diverse needs of its clients in the medical and research sectors.

Entia Ltd is a medical technology company based in London, United Kingdom, that focuses on enhancing access to blood tests through innovative healthcare devices. Founded in 2014, Entia offers two primary products: Aptus, a device for testing haemoglobin and haematocrit levels, and Affinity, designed for cancer patients to monitor their blood counts from home. These devices facilitate health screening, blood donor screening, maternal and child health, nutrition, and sports applications, while also enabling cancer patients to manage their health more effectively, reducing the risk of infection and minimizing hospital visits. The company employs a multidisciplinary team that encompasses design, engineering, quality assurance, and business development, all aimed at improving patients' quality of life by allowing them to conduct essential health monitoring from the comfort of their homes.

Oxford Heartbeat develops innovative medical device software designed to enhance the planning and execution of cardiovascular surgeries. The company's platform allows surgeons to visualize critical information about a patient's anatomy by providing insights into blood vessels, tissue, and bone structures. This advanced technology, which leverages predictive computations, big data, and artificial intelligence, enables medical professionals to rehearse procedures and select the most effective surgical scenarios tailored to individual patients. By improving surgical preparation, Oxford Heartbeat aims to reduce complication rates and associated healthcare costs while enhancing overall patient care. The company is currently conducting prospective clinical trials in NHS hospitals, supported by the UK government's AI in Health and Care Awards.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Azul Optics Limited is a medical device company based in Bristol, United Kingdom, founded in 2016. The company specializes in developing a device that rapidly assesses macular pigment density, an important indicator of eye health. This innovative device is designed to be affordable, fast, easy to use, and compact, facilitating the integration of macular pigment density screening into routine eye examinations. By informing patients about their levels of natural protection, the device empowers individuals with low defenses to take proactive measures for their eye health. Ultimately, Azul Optics aims to support eye health professionals in focusing on the prevention of age-related macular degeneration.

Renephra Ltd. is a medical device company based in Manchester, United Kingdom, established in 2009. It specializes in developing innovative Transdermal Fluid Removal (TFR) technology aimed at addressing fluid overload and chronic conditions such as oedema and lymphoedema. The company's devices utilize a micro-needle system combined with negative pressure therapy to facilitate minimally invasive fluid removal from the skin. This technology targets significant clinical needs within vascular and oncology patients, representing a large and underserved market estimated at £1 billion globally. Having achieved proof of concept in human trials, Renephra is currently seeking funding to advance its device development and feasibility studies.

DynamX Medical specializes in developing an innovative precancer screening system designed for rapid tissue biopsy analysis. This system is user-friendly and can be operated at the point of care by nurses, enhancing accessibility in clinical settings. The company's medical software aims to streamline the disease diagnosis process by increasing the speed and reliability of detection. This technology not only improves diagnostic efficiency but also helps healthcare institutions alleviate the strain on their resources. Through its advancements, DynamX Medical seeks to make significant contributions to early disease detection and patient care.

Sarissa Biomedical, Ltd. specializes in the development and production of innovative biosensors aimed at measuring neuroactive chemicals for research and clinical diagnostic purposes. The company focuses on creating minimally invasive, microelectrode electrochemical sensors that accurately measure purines and other neurochemicals, serving as indicators of neurological activity and disorders. These biosensors are suitable for both in vitro and in vivo studies. Additionally, Sarissa Biomedical is developing a hand-held point-of-care diagnostic device that utilizes finger-prick blood samples to identify individuals experiencing strokes. Founded in 2002 and based in Coventry, the United Kingdom, Sarissa Biomedical markets its products in various regions, including the United Kingdom, United States, Canada, and Japan.

Arterius Limited is focused on developing an innovative bio-resorbable coronary scaffold, commonly referred to as a stent. This next-generation device is designed to dissolve over a period of 12 to 24 months, becoming absorbed by the body, which eliminates the need for surgical removal. By offering a solution that minimizes the frequency of surgeries or medical interventions, Arterius aims to enhance the postoperative quality of life for patients. The scaffold is engineered to match the delivery ease of traditional bare metal and drug-eluting stents while reducing acute platelet adherence and thrombus formation, providing a safer and more effective alternative in cardiovascular treatments.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Glyconics Ltd. is a diagnostics company based in Cambridge, United Kingdom, specializing in the development of portable infrared spectroscopy devices for the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Established in 2013, the company has created a hand-held device that utilizes Fourier transform infrared spectroscopy (FTIR) to analyze sputum samples for specific biomarkers associated with COPD. This innovative technology allows patients to perform diagnoses and monitor their health from home, facilitating early detection and management of respiratory diseases. By identifying particular spectral signatures in the samples, the device supports healthcare professionals in assessing and understanding patients' conditions more effectively.

Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, that specializes in non-contact vital signs monitoring solutions. Founded in 2012, the company has developed the Oxecam software, which enables the measurement of heart rate, respiratory rate, and blood oxygenation using a digital video camera. This innovative system is particularly beneficial in healthcare settings, including mental health facilities and care homes, where staff may not always be present to monitor patients. Oxehealth's technology provides alerts for potentially risky activities and offers objective data for care planning, enhancing the ability of clinicians and caregivers to support vulnerable individuals. By employing advanced algorithms that utilize deep learning and computer vision, Oxehealth aims to improve patient monitoring and management while allowing staff more time for direct care. The company has achieved world-first certification for its software as a medical device, marking a significant advancement in remote patient monitoring.

MICA Biosystems specializes in the development of a cell stimulation platform that employs patented magnetic nanoparticle technology to influence cell behavior both in vitro and in vivo. Their innovative approach includes the creation of DYNASCREEN, a dynamic drug screening assay that leverages static magnetic forces to facilitate controlled cell differentiation and mechanical stimulation. This technology is particularly applicable in the fields of tissue engineering, biotechnology, and regenerative medicine, offering potential advancements in stem cell therapies aimed at treating bone and cartilage injuries. MICA's team is adept at functionalizing magnetic nanoparticles with various biological agents, including antibodies, peptides, and small molecules, to tailor solutions for diverse applications in health care and research.

Zilico Limited is a Manchester-based company focused on developing diagnostic devices aimed at improving cancer detection, particularly cervical cancer. Utilizing electrical impedance spectroscopy technology, Zilico's flagship product, ZedScan, operates alongside colposcopy to provide real-time, objective assessments of cervical epithelial tissue. This technology addresses the limitations of traditional diagnostic methods, which often involve subjective interpretations. Zilico is actively working on two applications: one targeting the referral market and another aimed at the screening market, both designed to enhance diagnostic accuracy and reduce the subjectivity associated with current practices. Since its founding in 2006, Zilico has aimed to deliver significant health economic benefits and improve cancer screening programs. The company was previously known as Aperio Diagnostics Limited before rebranding in 2008.